Davide Campari-Milano

Q2 FY24 – Campari has caught the flu

01/08/24 -"Although Campari’s results have been relatively resilient against a backdrop of soft market dynamics, the lack of sunshine leading to a negative mix is weighing on the Italian company. ..."

PDF page sample
Pages
58
Language
English
Published on
01/08/24
Download
You may also be interested by these reports :
16/06/26
Rémy (REDUCE; France) is not yet a clean turnaround story. It is a 300-year-old inventory model being tested by new drinking habits. After an almost ...
09/06/26
We have updated our model to incorporate the FY25/26 results. Sales came in at EUR 935.3m, broadly in line with our previous estimate of EUR 938m. ...
04/06/26
Rémy Cointreau’s FY 2025/26 results aligned closely with its targets, with a -11.5% organic decline in current operating profit. The strategic ...
04/06/26
In the second part of its FY25/26 release, Rémy Cointreau reports profitability following the sales figures disclosed in April. The key takeaway is a ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO